Hongwei Lin
- Pharmacology top 5%
- Drug-Induced Hepatotoxicity and Protection 3
- Civil and Structural Engineering top 10%
-
- Liver Diseases and Immunity 5
-
- Cancer Immunotherapy and Biomarkers 8
- CAR-T cell therapy research 7
-
- Liver Disease Diagnosis and Treatment 5
-
- Immunotherapy and Immune Responses 4
-
- Renal cell carcinoma treatment 3
- Gastric Cancer Management and Outcomes 3
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Hongwei Lin
44 papers receiving 763 citations
Hit Papers
Peers
Comparison fields: 5 of 114
- Pharmacology 95
- Cancer Research 81
- Civil and Structural Engineering 112
- Health, Toxicology and Mutagenesis 58
- Hepatology 32
Countries citing papers authored by Hongwei Lin
This map shows the geographic impact of Hongwei Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongwei Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongwei Lin more than expected).
Fields of papers citing papers by Hongwei Lin
This network shows the impact of papers produced by Hongwei Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongwei Lin. The network helps show where Hongwei Lin may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hongwei Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 6 | |
| 5 | 2024 | 1 | |
| 6 | 2023 | 22 | |
| 7 | 2023 | 26 | |
| 8 | 2022 | 9 | |
| 9 | 2022 | 21 | |
| 10 | 2021 | 1 | |
| 11 | 2021 | 13 | |
| 12 | 2021 | 46 | |
| 13 | 2020 | 5 | |
| 14 | 2020 | 14 | |
| 15 | 2020 | 2 | |
| 16 | 2020 | 35 | |
| 17 | 2019 | 1 | |
| 18 | 2019 | 26 | |
| 19 | 2012 | 84 | |
| 20 | 2010 | 49 |
About Hongwei Lin
Hongwei Lin is a scholar working on Hepatology, Pharmacology and Oncology, having authored 50 papers that have together received 770 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), CAR-T cell therapy research (7 papers), Liver Diseases and Immunity (5 papers), Liver Disease Diagnosis and Treatment (5 papers), Immunotherapy and Immune Responses (4 papers), Renal cell carcinoma treatment (3 papers), Gastric Cancer Management and Outcomes (3 papers) and Drug-Induced Hepatotoxicity and Protection (3 papers). The work is most often cited by research in Pharmacology (95 citations), Cancer Research (81 citations) and Civil and Structural Engineering (112 citations). Hongwei Lin has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Song Han, Changwei Shi, Fuyuan Gong, Siming Liang, Tongtong Pan, Da‐Zhi Chen, Ming Liu, Zhenxing Chi, Liqing Lin and Huihui Huang.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.